FDAnews
FDAnews Drug Daily Bulletin

SEROLOGICALS CORPORATION ANNOUNCES EXPANDED MULTI-YEAR DISTRIBUTION AGREEMENT WITH NOVO NORDISK

March 17, 2006

Celliance Corporation, a wholly owned subsidiary of Serologicals Corporation, announced today the execution of an expanded four-year supply agreement with Novo Nordisk A/S that provides Celliance the worldwide exclusive right to distribute Novo Nordisk's recombinant human insulin in the cell culture market. David A. Dodd, President and Chief Executive Officer of Serologicals Corporation, commented on the supply agreement, stating, "We are very pleased to have concluded this milestone agreement with Novo Nordisk. It represents years of hard work and successful collaboration on the part of both companies."

Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20060316005493&newsLang=en)